JFS Wealth Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

JFS Wealth Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.26K	Buy	27 +15	+125%	+$720	﹤0.01%	1751
2026 Q1	$621	Hold	12	–	–	﹤0.01%	1746
2025 Q4	$597	Buy	12 +3	+33%	+$146	﹤0.01%	1774
2025 Q3	$431	Sell	9 -2	-18%	-$81	﹤0.01%	1780
2025 Q2	$347	Buy	11 +9	+450%	+$288	﹤0.01%	1747
2025 Q1	$66	Sell	2 -11	-85%	-$390	﹤0.01%	1889
2024 Q4	$471	Hold	13	–	–	﹤0.01%	1787
2024 Q3	$406	Buy	13 +11	+550%	+$343	﹤0.01%	1821
2024 Q2	$54	Sell	2 -5	-71%	-$145	﹤0.01%	1954
2024 Q1	$239	Sell	7 -63	-90%	-$1.88K	﹤0.01%	1879
2023 Q4	$2.03K	Buy	70 +66	+1,650%	+$1.75K	﹤0.01%	1427
2023 Q3	$111	Sell	4 -2	-33%	-$61	﹤0.01%	1900
2023 Q2	$181	Buy	6 +3	+100%	+$105	﹤0.01%	1887
2023 Q1	$109	Buy	3 +2	+200%	+$77	﹤0.01%	1884
2022 Q4	$36	Buy	+1	New	+$35	﹤0.01%	1932

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

JFS Wealth Advisors's SUPN Position: Q2 2026 in Review

JFS Wealth Advisors increased its Supernus Pharmaceuticals (SUPN) stake by 125% in Q2 2026, buying an estimated $720 and bringing the position to 27 shares worth $1.26K. The position accounts for ﹤0.01% of the portfolio, ranked #1751.

JFS Wealth Advisors first reported a position in SUPN in Q4 2022 and has held it in 15 quarters since. The position peaked at $2.03K in Q4 2023. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

JFS Wealth Advisors held 27 shares of Supernus Pharmaceuticals worth $1.26K as of Q2 2026.
JFS Wealth Advisors bought 15 Supernus Pharmaceuticals shares in Q2 2026, an estimated $720.
Supernus Pharmaceuticals made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2026, its #1751 holding.
JFS Wealth Advisors first reported a position in Supernus Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
JFS Wealth Advisors's Supernus Pharmaceuticals position peaked at $2.03K in Q4 2023.
332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on JFS Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.